**Epigenetic alterations in TRAMP mice: genomic DNA methylation profiling using MeDIP-seq**

Wenji Li a,b,1, Ying Huang a,b,c,1, Davit Sargsyana,b,c, Tin Oo Khor a,b, YueGuo a,b,c, Limin Shu a,b, Anne Yuqing Yanga,b,c, Chengyue Zhang a,b,c, Ximena Paredes-Gonzalez a,b,c, Michael Verzi d, Ronald P Hart e, and Ah-Ng Kong a,b,\*

aCenter for Phytochemical Epigenome Studies, Ernest Mario School of Pharmacy, The State University of New Jersey, Piscataway, NJ 08854, USA.

bDepartment of Pharmaceutics, Ernest Mario School of Pharmacy, The State University of New Jersey, Piscataway, NJ 08854, USA.

cGraduate Program in Pharmaceutical Sciences, Ernest Mario School of Pharmacy, The State University of New Jersey, Piscataway, NJ 08854, USA.

dDepartment of Genetics, The State University of New Jersey, Piscataway, NJ 08854, USA.

eDepartment of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.

1Equal contribution

\*Correspondence should be addressed to:

Professor Ah-Ng Tony Kong

Rutgers, The State University of New Jersey

Ernest Mario School of Pharmacy, Room 228

160 Frelinghuysen Road,

Piscataway, NJ 08854, USA

Email: kongt@pharmacy.rutgers.edu

Phone: 848-445-6369/8

Fax: 732-445-3134

Color figures are intended for reproduction in color on the Web and in black-and-white in print

This work was supported in part by institutional funds and by R01 AT007065-01and AT009152 from the National Center for Complementary and Integrative Health (NCCIH) and R01 CA200129, from the National Cancer Institute (NCI).

Abbreviations:

TRAMP-Transgenic adenocarcinoma of the mouse prostate

MeDIP - Methylated DNA immunoprecipitation

IPA- Ingenuity® pathway analysis

CREB1-Cyclic AMP (cAMP) response element-binding protein 1

HDAC2- Histone deacetyltransferase 2

GSTP1-Glutathione S-transferase 1

UBC-Ubiquitin C

Keywords: MeDIP-seq, Epigenetics, DNA methylation, TRAMP, Prostate Cancer

**Abstract**

**Purpose:** We investigated the genomic DNA methylation profile of prostate cancer in transgenic adenocarcinoma of the mouse prostate (TRAMP) cancer model and to analyze the crosstalk among targeted genes and the related functional pathways.

**Methods:** Prostate DNA samples from 24-week-old TRAMP and C57BL/6 male mice were isolated. The DNA methylation profiles were analyzed by methylated DNA immunoprecipitation (MeDIP) followed by next-generation sequencing (MeDIP-seq). Canonical pathways, diseases & function and network analyses of the different samples were then performed using the Ingenuity® Pathway Analysis (IPA) software. Some genes were randomly selected for validation using Methylation Specific Primers (MSP) and qPCR.

**Results:** TRAMP mice undergo extensive aberrant CpG hyper- and hypo-methylation. There were 2,147 genes with a significant (log2-fold change ≥2) change in CpG methylation peaks between the two groups, as mapped by the IPA software. Among these genes, the methylation of 1,105 and 1,042 genes was significantly decreased and increased, respectively, in TRAMP prostate tumors.The top associated disease identified by IPA was adenocarcinoma; however, the CREB-, HDAC2-, GSTP1- and UBC-related pathways showed significantly altered methylation profiles based on the canonical pathway and network analyses. MSP and qPCR results of randomly selected genes corroborated with MeDIP-seq.

**Conclusions****:** This is the first MeDIP-seq with IPA analysis of the TRAMP model to provide novel insight into the genome-wide methylation profile of prostate cancer. Studies on epigenetics, such as DNA methylation, will potentially provide novel avenues and strategies for further development of biomarkers targeted for treatment and prevention approaches for prostate cancer.

**Introduction**

Prostate cancer is the second most common cancer of men (914 000 new cases, 13.8% of the total) and the fifth most common among all cancers [[1](#_ENREF_1)]. In the United States, prostate cancer is the most common male cancer subtype, apart from non-melanoma skin cancer [[2](#_ENREF_2)]. Prostate cancer is a clinically heterogeneous disease with marked variability in patient outcomes [[3](#_ENREF_3)]. Early detection, accurate prediction and successful management of prostate cancer represent some of the most challenging and controversial issues [[4](#_ENREF_4)]. Interestingly, epigenetic changes are hallmarks of prostate cancer, among which DNA methylation is the most frequently studied [[5](#_ENREF_5)].

Epigenetic changes include DNA methylation, histone modification, and posttranslational gene regulation by micro-RNAs (miRNAs) [[6](#_ENREF_6)]. Among these, DNA methylation has been well studied, and aberrant DNA methylation patterns are a characteristic feature of cancer [[7](#_ENREF_7), [8](#_ENREF_8)]. The first reported epigenetic changes in human cancer were DNA methylation losses [[9](#_ENREF_9)]. Since then, genomic hypomethylation has been found to be associated with multiple cancer types [[10](#_ENREF_10), [11](#_ENREF_11)]. In addition, hypermethylation of CpG islands (CGIs) at promoters of tumor suppressor genes, homeobox genes and other sequences are other consistent epigenetic features of cancer [[12](#_ENREF_12)]. CGI methylator-phenotype (CIMP) tumors have been identified in many cancers, including oral cancer [[13](#_ENREF_13)], colorectal cancer [[14](#_ENREF_14)] and colon cancer [[15](#_ENREF_15)]. Therefore, it is worthwhile to profile the global DNA methylation changes between cancer models and controls to elucidate the mechanisms of carcinogenesis.

The transgenic adenocarcinoma of the mouse prostate (TRAMP) model closely represents the pathogenesis of human prostate cancer because male TRAMP mice spontaneously develop autochthonous prostate tumors following the onset of puberty [[16](#_ENREF_16)] and it specifically induces transgene expression in the prostate, displays distant organ metastases and it has castration-resistant properties [[17](#_ENREF_17)]. DNA methylation in the TRAMP model has been widely studied *in vitro* and *in vivo*, resulting in the discovery of the methylated markers Nrf2 [[18](#_ENREF_18)], MGMT[[19](#_ENREF_19)], GSTP1 [[20](#_ENREF_20)], 14-3-3σ [[21](#_ENREF_21)], and KLF6 [[22](#_ENREF_22)].

However, only Shannon et al have compared global methylation alteration among TRAMP and WT mice [[23](#_ENREF_23)]. Systemic comparisons and analyses of the genomic methylation status of prostate cancer models and normal controls are needed to determine the underlying interactions between these target genes and to discover new biomarkers. We are the first to perform methylated DNA immunoprecipitation (MeDIP) coupled with next-generation sequencing (MeDIP-seq) followed by Ingenuity® Pathway Analysis (IPA) studies to investigate the crosstalk among important genes and to analyze overlapping functional pathways by comparing the whole genomic DNA methylation patterns between the TRAMP model and controls.

**Materials and methods**

**Genomic DNA extraction from TRAMP and C57BL/6 male mice**

The breeding of TRAMP mice were followed our previous publication [[24](#_ENREF_24), [25](#_ENREF_25)]. Briefly, female hemizygous C57BL/TGN TRAMP mice, line PB Tag 8247NG (Jackson Laboratory, Bar Harbor, ME), were bred with the same genetic background male C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME). Identity of transgenic mice was established by PCR-based DNA genotyping using the primers suggested by The Jackson Laboratory as we previously described [[24](#_ENREF_24), [25](#_ENREF_25)]. F1 (first generation from cross breeding) or F2 (second generation from cross breeding) male TRAMP mice were used for the studies). Mice were housed in cages containing wood-chip bedding in a temperature-controlled room (20–22°C) with a 12-h-light/dark cycle and a relative humidity of 45–55% at Rutgers Animal Care Facility. All animals received water and food *ad libitum* until sacrifice (24 weeks of age) by carbon dioxide euthanasia. The study was performed using an IACUC-approved protocol at Rutgers University. Mice were weighted and evaluated in the overall health twice weekly during all the study. Presences of palpable tumor, metastases, genitourinary (GU) apparatus weight were evaluated upon necropsy and prostate intraepithelial neoplasia lesions (evaluated by H&E staining) were monitored in the TRAMP group (data not shown). Prostate samples from three 24-week-old TRAMP and three 24 weeks old C57BL/6 mice (maintained under similar conditions) were randomly selected out. A DNeasy Kit (Qiagen, Valencia, CA, USA) was used to extract the genomic DNA (gDNA) from prostate samples of three 24-week-old male TRAMP mice and three age-matched C57BL/6 male mice according to the manufacturer's protocol. After extraction and purification, the gDNA samples were electrophoresed on an agarose gel, and the OD ratios were measured to confirm the purity and concentrations of the gDNA prior to fragmentation by Covaris (Covaris, Inc., Woburn, MA USA). The fragmented gDNA was then evaluated for size distribution and concentration using an Agilent Bioanalyzer 2100 and a NanoDrop spectrophotometer.

**MeDIP-seq measurement**

Following the manufacturer's instructions, MeDIP was performed to analyze genome-wide methylation using the MagMeDIP Kit from Diagenode (Diagenode Inc., Denville, NJ, USA). Methylated DNA was separated from unmethylated fragments by immunoprecipitation with a 5-methylcytidine monoclonal antibody that was purchased from Eurogentec (Eurogentec S.A., Seraing, Belgium). Illumina libraries were then created from the captured gDNA using NEBNext reagents (New England Biolabs, Ipswich, MA, USA). Enriched libraries were evaluated for size distribution and concentration using an Agilent Bioanalyzer 2100, and the samples were then sequenced on an Illumina HiSeq2000 machine, which generated paired-end reads of 90 or 100 nucleotides (nt). The results were analyzed for data quality and exome coverage using the platform provided by DNAnexus (DNAnexus, Inc., Mountain View, CA, USA). The samples were sent to Otogenetics Corp. (Norcross, GA) for Illumina sequencing and alignment with the genome. The resulting BAM files were downloaded for analysis.

Modified from the Trapnell method, the MeDIP alignments were compared with control sample alignments using Cuffdiff 2.0.2 with no length correction [[26](#_ENREF_26)]. Briefly, a list of overlapping regions of sequence alignment that were common to both the immunoprecipitated and control samples was created and used to determine the quantitative enrichment of the MeDIP samples over the control samples using Cuffdiff; statistically significant peaks (reads) at a 5% false discovery rate (FDR) and a minimum 4-fold difference, as calculated using the Cummerbund package in R, were selected (Trapnell et al., 2012). Sequencing reads were matched with the adjacent annotated genes using ChIPpeakAnno [[27](#_ENREF_27)], and the uniquely mapped reads were used to compare the differences between TRAMP and wild-type mice.

**Canonical pathways, diseases & function and network analysis by IPA**

Genes selected from the MeDIP-seq experiment based on significant increased or decreased fold changes (log2-fold change ≥ 2) in the methylation pattern were analyzed (based on the p-values; TRAMP vs. control) using IPA 4.0 When using IPA (IPA 4.0, Ingenuity Systems, www.ingenuity.com), the pathway enrichment p-value is calculated using the right-tailed Fisher Exact Test*.* A smaller *p*-value indicated that the association was less likely to be random and more likely to be significant. In general, values of 0.05 (for *p*-value) or 1.30 (for –log10P) were set as the thresholds. P-values less than 0.05 or –log10P more than 1.30 were considered to be statistically significant, non-random associations. IPA utilized gene symbols to identify neighboring enriched methylation peaks using ChIPpeakAnno for all of the analyses. Using IPA, 2147 genes in the TRAMP group that showed a log2-fold change ≥ 2 compared with the control group were mapped. Based on these fold changes, IPA identified the canonical pathways, biological functions/related diseases and networks that were closely related to the TRAMP model.

**MeDIP-seq data validation via Methylation-specific PCR (MSP)**

Genomic DNA was extracted from six prostate samples (three from TRAMP mice and three from normal C57BL/6 mice)using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Valencia, CA, USA). Then 500 ng of genomic DNA was subjected to bisulfite conversion with an EZ DNA Methylation-Gold Kit (Zymo Research Corp., Orange, CA) according to the manufacturer’s instructions as described previously [[28](#_ENREF_28)]. The converted DNA was amplified by PCR using EpiTaq HS DNA polymerase (Clontech Laboratories Inc, Mountain View, CA 94043, USA). According to MeDIP-seq results, four genes (2 with increased methylation and 2 with decreased methylation), Dync1i1, Slc1a4, Xrcc6bp1 and TTR, were randomly selected for MSP validation. The primers’ sequences for the methylated reactions (MF and MR) and for the unmethylated reactions (UF and UR) and band size of products are listed in Table 1. The amplification products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining using a Gel Documentation 2000 system (Bio-Rad, Hercules, CA, USA). The bands were semi-quantitated by densitometry using ImageJ (Version 1.48d; NIH, Bethesda, Maryland, USA).

**Validation of selected gene expression by Real-time RT-PCR**

Total RNA was extracted from six prostate samples (three from TRAMP mice and three from normal C57BL/6 mice) using the AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Valencia, CA, USA). First-strand cDNA was synthesized from total RNA using a SuperScript III First-Strand Synthesis System (Invitrogen, Grand Island, NY) according to the manufacturer’s instructions. mRNA expression levels were determined using first strand cDNA as the template by quantitative real-time PCR (qPCR) with Power SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) in an ABI7900HT system. HNMT, Dync1i1, SLC1A4, Cryz and TTR were randomly selected to compare mRNA expression among WT and TRAMP mice prostate samples. The primers’ sequences for HNMT, Dync1i1, SLC1A4, Cryz, TTR and β-Actin are listed in Table 2.

**Results**

**MeDIP-seq results comparison**

A primary goal of the study was to identify aberrantly methylated genes and discover the related functions and pathways that might mediate the development of prostate cancer. To accomplish this objective in an unbiased manner, the MeDIP-seq results were analyzed using IPA. The first objective was to compare the total number of molecules with altered methylation in prostate samples of TRAMP mice to that of normal mice. Prostate samples were collected from the TRAMP and C57BL/6 mice, gDNA was isolated, and whole-genome DNA methylation analysis was performed using the described MeDIP-seq method. The results were analyzed in a paired manner, comparing the prostate tissue samples for each model. For the control, 16 509 344 (80.8%) mapped reads and 3 921 684 (19.2%) non-mapped reads, for a total of 20 431 028 reads, were obtained. For the TRAMP mice, 12 097 771 (82.3%) mapped reads and 2 609 269 (17.7%) non-mapped reads, for a total of 14 707 040 reads, were obtained (Fig. 1A). After identification and mapping to the library, the identified methylated regions (peaks) of the given genes were compared between the TRAMP and control mice, and IPA was used to identify the genes with significantly altered methylation in the TRAMP mice compared with the controls (*p*<0.05 or –log10P>1.30, and log2-fold change ≥2).

According to the IPA setting , the *p*-value for a given process annotation was calculated by considering (1) the number of focus genes that participated in the process and (2) the total number of genes that are known to be associated with that process in the selected reference set. The more focus genes that are involved, the more likely the association is not due to random chance, resulting in a more significant p-value (larger –log10P-value). Altogether, 2147 genes between the two groups showed a significant change (log2-fold change ≥2) in methylated peaks. Compared with the control, significantly decreased methylation of 1105genes and significantly increased methylation of 1042genes were observed in TRAMP (Fig. 1B). The top 50 genes with increased methylation (Table 3) or decreased methylation (Table 4) located in promoter region, gene body or downstream of the gene were highlighted based on the log2-fold change, from highest to lowest; all *p*-values were less than 0.05. We also plotted the top 100 decreased or increased (Log2-fold Change) methylated genes comparing with TRAMP to WT in different regions by MeDIP analysis, ranked by alphabet (Fig 2).

These results demonstrate a fundamental difference in the global pattern of gene methylation between the TRAMP prostate tumor and control prostate tissue. The potential impact of this difference was further assessed using IPA by analyzing the canonical pathways, diseases and functions, and networks related to these methylation changes.

**MeDIP-seq data validation by MSP**

According to the MeDIP-seq results, two genes with increased methylation (TRAMP vs WT), Dync1i1 and Slc1a4, and two genes with decreased methylation (TRAMP vs WT), Xrcc6bp1 and TTR were selected randomly to carry out MSP to validate the MeDIP-seq data. MSP results indicated a similar trend in agreement with the MeDIP-seq results.

The results showed, in Dync1i1 and Slc1a4 genes, the relative density of M-MSP (methylated MSP) to that of U-MSP (unmethylated MSP) in TRAMP group were increased, which indicated that the CpG sites of these genes were hypermethylated in TRAMP mice (Fig. 3). Similarly, in Xrcc6bp1 and TTR, the relative density of M-MSP to that of U-MSP in TRAMP group was decreased, which indicated that the CpG sites of these genes were hypomethylated in TRAMP mice (Fig. 3).

**qPCR Validation of selected gene expression**

When mRNA levels were measured by qPCR, the relative expression levels of Cryz, Dync1i1, Hnmt, Slc1a4 and Ttr in TRAMP group were 0.62, 1.90, 0.15, 0.15 and 9.05 fold compared with WT (Fig. 4).Among these,Ttr expression was increased by 9.05-fold over WT, which agreed with results reported by Wang et al. that expression levels of TTR were significantly higher in Prostate cancer tissue than in normal and benign prostate hyperplasia tissue [[29](#_ENREF_29)]. When comparing mRNA expression and Methylation validation results, reciprocal relationships were found in TTR in TRAMP, which indicated decreased methylation in promoter region but increased gene expression when comparing with WT. In contrast, DNA methylation in the gene body or downstream may or may not follow a reciprocal relationship with gene expression as described in the findings of Yi-Zhou Jiang et.al. [[30](#_ENREF_30)]. It is expected that individual genes may be differentially affected by CpG methylation and that only global analysis would be expected to reveal overall patterns likely to emerge.

**Canonical pathway, diseases & functions and network analyses by IPA**

To ascertain the significance of the methylation changes, the 2147 genes with a greater than log2-fold change in methylation were analyzed using the IPA software package. When using IPA, canonical pathways, which are based on the literature and are generated prior to data input, are the default settings. These pathways do not change upon data input and have a directionality-linked list of interconnected nodes. By contrast, networks are generated *de novo* based upon input data, lack directionality and contain molecules that are involved in a variety of canonical pathways.

The genes within the canonical pathways were ranked by the possibility parameter, i.e., the –log10(P) value in the corresponding pathway, and are presented in Table 5. The CREB1 gene, which is involved the neuropathic pain signaling pathway, was ranked first. The top networks ranked based on their ratios of methylated gene/total gene are listed in Table 6. Of the networks, the histone deacetyltransferase 2 (HDAC2)-related, tissue morphology, embryonic development, and organ development network was ranked first (Table 6). Among the networks, the cancer-related networks accounted for the majority (15/25) (Table 6), which indicates that the great difference between the TRAMP and control lies in organ development and cancer development.

Diseases & functions refer to the most likely linked diseases or functions based on statistics. Similar to the network analysis, for the most associated disease based on the ranking of –log10P, cancer, gastrointestinal disease, organismal abnormalities, reproductive system disease and dermatological diseases were ranked within the top 5 (Fig. 5A). Of all cancer subtypes, adenocarcinoma ranked first (Fig. 5B), which was consistent with the TRAMP model, which is a model for prostate adenocarcinoma.

**Discussion**

**Useful canonical pathway analysis will provide further understanding of disease and information for the development of new therapeutic targets.**

As shown in Fig. 6, the genes with significantly altered methylation in the top canonical pathway was the neuropathic pain signaling pathway, as mapped by IPA. This finding is consistent with Chiaverotti’s finding indicating that the most common malignancy in TRAMP is of neuroendocrine origin [[31](#_ENREF_31)]. Table 7 lists the genes involved in this pathway that exhibited modified methylation. Among these, methylation of the cyclic AMP (cAMP) response element-binding protein 1 (CREB1) gene was found to be decreased by 2.274-fold (log2) by MeDIP-seq in TRAMP.

CREB was first found to be closely related to cellular proliferation, differentiation and adaptive responses in the neuronal system [[32](#_ENREF_32), [33](#_ENREF_33)]. Subsequently, increasing evidence revealed that CREB is directly involved in the oncogenesis of a variety of cancers by regulating the immortalization and transformation of cancer cells. [[34](#_ENREF_34), [35](#_ENREF_35)].

CREB is also found to modulate other carcinogenesis pathways. S100P is a calcium-binding protein that is associated with cancer, and functional analysis of the S100P promoter identified SMAD, STAT/CREB and SP/KLF binding sites as key regulatory elements in the transcriptional activation of the S100P gene in cancer cells [[36](#_ENREF_36)]. *Homo sapiens* lactate dehydrogenase c (hLdhc) was reported to be expressed in a wide spectrum of tumors, including prostate cancers, and this expression was shown to be regulated by transcription factor Sp1 and CREB as well as promoter CpG island (CGI) methylation [[37](#_ENREF_37)]. Decreased prostate tumorigenicity was found to be correlated with decreased expression of CREB and its targets, including Bcl-2 and cyclin A1 [[38](#_ENREF_38)].

Clinically, overexpression and overactivation of CREB was observed in cancer tissues from patients with prostate cancer, breast cancer, non-small-cell lung cancer and acute leukemia, whereas down-regulation of CREB in several distinct cancer cell lines resulted in the inhibition of cell proliferation and induction of apoptosis [[39](#_ENREF_39)].

All of these data indicate that CREB is highly associated with cancer therapy. Our study demonstrated that CREB gene methylation is significantly decreased in the TRAMP model, which suggests a new approach to prostate cancer prevention and therapy.

**Novel networks involving the methylation of target genes could provide new insights for prostate cancer.**

Compared with the canonical pathways, networks are generated *de novo* based upon input data and are able to more flexibly reveal the interactions of altered genes and functions. As it is impossible to analyze all networks listed in Table 6, four interesting networks were elaborated below (the higher the score is, the more genes with altered methylation are involved in the network). Among all these networks, many genes are known to be highly associated with tumor onset and progression, however, our insight into their methylation status alteration would reveal novel biomarkers for prostate tumorigenesis.

HDAC2-related network (Score=38): The top network identified by IPA, was the HDAC2-related tissue morphology, embryonic development and organ development network (Table 6, Fig. 7A). In this network, the HDAC2 gene, a key member of HDAC, exhibited 3.274-fold (log2) decreased methylation in TRAMP. HDACs are responsible for the removal of acetyl groups from histones and play important roles in modulating the epigenetic process by influencing the expression of genes encoded by DNA bound to a histone molecule [[40](#_ENREF_40)]. HDAC inhibitors have also been shown to reduce colonic inflammation [[41](#_ENREF_41)], inhibit cell proliferation, and stimulate apoptosis, and these inhibitors represent a novel class of therapeutic agents with antitumor activity that are currently in clinical development [[42](#_ENREF_42), [43](#_ENREF_43)]. By upregulating histone H3 acetylation and p21 gene expression, long-term treatment with MS-275, an HDAC inhibitor, attenuated the progression of prostate cancer *in vitro* and *in vivo* [[44](#_ENREF_44)]. Another HDAC inhibitor, OSU-HDAC42, also showed a chemoprevention effect on prostate tumor progression in the TRAMP model [[45](#_ENREF_45)]. Our data suggest that the altered methylation of HDAC (3.274 Log2-fold decrease) might be a novel, interesting target for prostate cancer treatment. Based on our MeDIP-seq results, the methylation of histamine N-methyltransferase (HNMT) in this network was increased by 3.703-fold (Log2). In addition, based on our qPCR analysis, HNMT gene expression was reduced by 6.67-fold, which supports the likelihood of a role of HNMT in prostate cancer. However, although HNMT has been demonstrated to be associated with breast cancer [[46](#_ENREF_46)] and liver cancer [[47](#_ENREF_47)], little is known about its potential role in prostate cancer, making it another potential novel marker.

Glutathione S-transferase 1 (GSTP1)-related network(Score=16): GSTP1 expression is inactivated in prostate cancers [[48-50](#_ENREF_48)], and this inactivation is associated with hypermethylation of GSTP1 CpG islands [[49](#_ENREF_49), [50](#_ENREF_50)]. Clinically, higher GSTP1 promoter methylation was found to be independently associated with the risk of prostate cancer [[51](#_ENREF_51)]; therefore, the detection of hypermethylated GSTP1 in urine and semen samples can be a diagnostic marker of prostate cancer [[52](#_ENREF_52)]. We also found that methylation of GSTP1 was an important factor involved in prostate cancer development. Interestingly, based on our data, the methylation of the GSTP1 gene was decreased 2.274-fold (log2) in TRAMP. Fig. 7B demonstrates the decreased methylation of GSTP1. Based on comparisons of prostate samples from TRAMP and strain-matched WT mice, Mavis CK et al. showed that promoter DNA hypermethylation does not appear to drive GST gene repression in TRAMP primary tumors [[20](#_ENREF_20)]. The above results support our finding that the methylation status of GSTP1 may differ in humans. Dynein cytoplasmic 1 intermediate chain 1 (DYNC1I1), which was also in the network, exhibited a 4.926-fold (Log2) increase in methylation. In qPCR analysis, it indicates a 1.9-fold increase in gene expression. Although DYNC1I1 is significantly up-regulated in liver tumors [[53](#_ENREF_53)] but not in prostate tumors, our findings suggest that it may be the next useful prostate cancer biomarker.

Ubiquitin C (UBC)-related network (Score=16)*:* Another interesting network was found surrounding the UBC gene (Fig. 7C); however, UBC itself was not identified by MeDIP-seq. The methylation of solute carrier family 1 member 4 (SLC1A4) and crystallin zeta (CRYZ) was highly up-regulated (3.807 and 3.703 Log2-fold increased, respectively). According to qPCR results, the expressions of SLC1A4 and CRYZ in TRAMP group were only 0.15 and 0.62 fold of WT group. SLC1A4 was found to be associated with human hepatocellular carcinoma [[54](#_ENREF_54)], and CRYZ was proven to be involved in BCL-2 overexpression in T-cell acute lymphocytic leukemia [[55](#_ENREF_55)]. Although an association with prostate cancer was not found, our MeDIP–seq findings in the TRAMP model suggest that this association is possible.

Merged networks overlaid with IPA settings could even predict the direction of the relationship.When merging the two interesting networks HDAC2 and GSTP1 and overlaying the molecular activity predictor of IPA (Fig. 8), tumor protein 53 (TP53) was found to be located in the center of the novel network, indicating the potential important modulating function of TP53 on HDAC2 and GSTP1. TP53 is encoded by p53, a tumor suppressor gene located on chromosome 17p13, which is one of the most frequently mutated genes in various types of cancers [[56-58](#_ENREF_56)]. TP53 acts as a transcription factor that mediates the response to many cellular stresses, most prominently, the DNA damage response [[59](#_ENREF_59)]. TP53 has also been proven to play a crucial role in prostate cancer development and progression [[60-62](#_ENREF_60)].

The interactions between GSTP1, HDAC and TP53 have been studied in prostate disease models. In prostatectomy specimens of 30 benign prostatic hyperplasia patients, the increase in TP53 expression at the same site was accompanied by an increase in GSTP1expression [[63](#_ENREF_63)]. In the three prostate cancer cell lines DU-145, PC-3 and LNCaP, As2O3 was found to increase TP53 expression only in LNCap cells (without GSTP1 expression) but not in DU-145 and PC-3 cells (both cells expressed GSTP1) [[64](#_ENREF_64)]. In LNCaP cells, the acetylation of human TP53 increased the binding of promoter fragments of the human P21 gene that contained a p53 response element and of the human HDAC2 protein [[65](#_ENREF_65)].

Although the relationships between TP53 and HDAC2 as well as GSTP1 in prostate cancer have been elucidated, these relationships in the TRAMP model remain unknown. Our predicated interactions among these proteins in TRAMP suggest the possibility that TP53 influences the methylation of GSTP1 and HDAC2, which is a potential direction of future research.

**Conclusions**

To the best of our knowledge, this is the first MeDIP-seq study to analyze the DNA methylation differences of prostate cancer by comparing TRAMP mice, an adenocarcinoma prostate cancer model, with wild-type C57BL/6 mice. Cancer, especially adenocarcinoma, is the most commonly associated disease. MSP and qPCR have been used to validate the findings of MeDIP-seq. Using this MeDIP-seq and IPA analysis, comparisons between the TRAMP and control samples reveal profound differences in gene methylation. The analysis of canonical pathways and networks has identified important biological functions and molecular pathways that may mediate the development of adenocarcinoma prostate cancer. CREB-, HDAC2-, GSTP1- and UBC-related pathways showed significantly altered methylation profiles based on the canonical pathway and network analyses. Studies on epigenetics, such as DNA methylation, suggest novel avenues and strategies for the further development of biomarkers targeted for treatment and prevention approaches for prostate cancer.

**Conflict of interest statement**

The authors declare that there are no conflicts of interest.

**Authors’ contributions**

Wenji Li designed the experiments. Wenji Li, Ying Huang and Davit Sargsyan performed the experiments and acquired the data. All authors prepared the manuscript. All authors read and approved the fnal manuscript.

**Acknowledgments**

The authors express sincere gratitude to all of the members of Dr. Tony Kong's laboratory for their helpful discussions. This work was supported in part by institutional funds and by R01-CA118947, R01-CA152826, and R01-CA200129 from the National Cancer Institute (NCI), R01-AT009152 from the National Center for Complementary and Integrative Health (NCCIH), and R01-AT007065 from NCCIH and the Office of Dietary Supplements (ODS).

**References**

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: **Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.** *International journal of cancer* 2010, **127:**2893-2917.

2.  **United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report.** [<http://apps.nccd.cdc.gov/uscs/>]

3. Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T, Rubin MA: **The mutational landscape of prostate cancer.** *Eur Urol* 2013, **64:**567-576.

4. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et al: **Prevention and early detection of prostate cancer.** *Lancet Oncol* 2014, **15:**e484-e492.

5. Strand SH, Orntoft TF, Sorensen KD: **Prognostic DNA Methylation Markers for Prostate Cancer.** *Int J Mol Sci* 2014, **15:**16544-16576.

6. Matei DE, Nephew KP: **Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.** *Gynecol Oncol* 2010, **116:**195-201.

7. Jeong M, Goodell MA: **New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells.** *Exp Hematol* 2014, **42:**609-617.

8. Ushijima T, Watanabe N, Okochi E, Kaneda A, Sugimura T, Miyamoto K: **Fidelity of the methylation pattern and its variation in the genome.** *Genome Res* 2003, **13:**868-874.

9. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M: **The 5-methylcytosine content of DNA from human tumors.** *Nucleic Acids Res* 1983, **11:**6883-6894.

10. Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J, Speights VO, Isaac J, Rohr LR: **Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?** *Cancer Genet Cytogenet* 2005, **156:**31-36.

11. Seifert HH, Schmiemann V, Mueller M, Kazimirek M, Onofre F, Neuhausen A, Florl AR, Ackermann R, Boecking A, Schulz WA, Grote HJ: **In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer.** *Exp Mol Pathol* 2007, **82:**292-297.

12. Issa JP: **CpG island methylator phenotype in cancer.** *Nat Rev Cancer* 2004, **4:**988-993.

13. Shaw RJ, Hall GL, Lowe D, Bowers NL, Liloglou T, Field JK, Woolgar JA, Risk JM: **CpG island methylation phenotype (CIMP) in oral cancer: associated with a marked inflammatory response and less aggressive tumour biology.** *Oral Oncol* 2007, **43:**878-886.

14. Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA, Zali MR: **The CpG island methylator phenotype (CIMP) in colorectal cancer.** *Gastroenterol Hepatol Bed Bench* 2013, **6:**120-128.

15. Berg M, Hagland HR, Soreide K: **Comparison of CpG island methylator phenotype (CIMP) frequency in colon cancer using different probe- and gene-specific scoring alternatives on recommended multi-gene panels.** *PLoS One* 2014, **9:**e86657.

16. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED: **The TRAMP mouse as a model for prostate cancer.** *Curr Protoc Immunol* 2001, **Chapter 20:**Unit 20 25.

17. Valkenburg KC, Williams BO: **Mouse models of prostate cancer.** *Prostate Cancer* 2011, **2011:**895238.

18. Yu S, Khor TO, Cheung KL, Li W, Wu TY, Huang Y, Foster BA, Kan YW, Kong AN: **Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice.** *PLoS One* 2010, **5:**e8579.

19. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, Day ML: **Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer.** *Cancer Res* 2006, **66:**385-392.

20. Mavis CK, Morey Kinney SR, Foster BA, Karpf AR: **Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.** *Prostate* 2009, **69:**1312-1324.

21. Pulukuri SM, Rao JS: **CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.** *Oncogene* 2006, **25:**4559-4572.

22. Chiam K, Ryan NK, Ricciardelli C, Day TK, Buchanan G, Ochnik AM, Murti K, Selth LA, Australian Prostate Cancer B, Butler LM, et al: **Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers.** *Prostate* 2013, **73:**182-193.

23. Morey Kinney SR, Zhang W, Pascual M, Greally JM, Gillard BM, Karasik E, Foster BA, Karpf AR: **Lack of evidence for green tea polyphenols as DNA methylation inhibitors in murine prostate.** *Cancer Prev Res (Phila)* 2009, **2:**1065-1075.

24. Wu TY, Khor TO, Su ZY, Saw CL, Shu L, Cheung KL, Huang Y, Yu S, Kong AN: **Epigenetic modifications of Nrf2 by 3,3'-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors.** *AAPS J* 2013, **15:**864-874.

25. Khor TO, Yu S, Barve A, Hao X, Hong JL, Lin W, Foster B, Huang MT, Newmark HL, Kong AN: **Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model.** *Cancer Res* 2009, **69:**7096-7102.

26. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L: **Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks.** *Nat Protoc* 2012, **7:**562-578.

27. Zhu LJ, Gazin C, Lawson ND, Pages H, Lin SM, Lapointe DS, Green MR: **ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data.** *BMC Bioinformatics* 2010, **11:**237.

28. Khor TO, Huang Y, Wu TY, Shu L, Lee J, Kong AN: **Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation.** *Biochem Pharmacol* 2011, **82:**1073-1078.

29. Wang D, Liang H, Mao X, Liu W, Li M, Qiu S: **Changes of transthyretin and clusterin after androgen ablation therapy and correlation with prostate cancer malignancy.** *Transl Oncol* 2012, **5:**124-132.

30. Jiang YZ, Manduchi E, Stoeckert CJ, Jr., Davies PF: **Arterial endothelial methylome: differential DNA methylation in athero-susceptible disturbed flow regions in vivo.** *BMC Genomics* 2015, **16:**506.

31. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, Balmain A: **Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.** *Am J Pathol* 2008, **172:**236-246.

32. Mayr B, Montminy M: **Transcriptional regulation by the phosphorylation-dependent factor CREB.** *Nat Rev Mol Cell Biol* 2001, **2:**599-609.

33. Shaywitz AJ, Greenberg ME: **CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals.** *Annu Rev Biochem* 1999, **68:**821-861.

34. Sakamoto KM, Frank DA: **CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy.** *Clin Cancer Res* 2009, **15:**2583-2587.

35. Conkright MD, Montminy M: **CREB: the unindicted cancer co-conspirator.** *Trends Cell Biol* 2005, **15:**457-459.

36. Gibadulinova A, Tothova V, Pastorek J, Pastorekova S: **Transcriptional regulation and functional implication of S100P in cancer.** *Amino Acids* 2011, **41:**885-892.

37. Tang H, Goldberg E: **Homo sapiens lactate dehydrogenase c (Ldhc) gene expression in cancer cells is regulated by transcription factor Sp1, CREB, and CpG island methylation.** *J Androl* 2009, **30:**157-167.

38. Park MH, Lee HS, Lee CS, You ST, Kim DJ, Park BH, Kang MJ, Heo WD, Shin EY, Schwartz MA, Kim EG: **p21-Activated kinase 4 promotes prostate cancer progression through CREB.** *Oncogene* 2013, **32:**2475-2482.

39. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM: **Targeting CREB for cancer therapy: friend or foe.** *Curr Cancer Drug Targets* 2010, **10:**384-391.

40. Bassett SA, Barnett MP: **The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease.** *Nutrients* 2014, **6:**4273-4301.

41. Glauben R, Batra A, Stroh T, Erben U, Fedke I, Lehr HA, Leoni F, Mascagni P, Dinarello CA, Zeitz M, Siegmund B: **Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.** *Gut* 2008, **57:**613-622.

42. Giannini G, Cabri W, Fattorusso C, Rodriquez M: **Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.** *Future Med Chem* 2012, **4:**1439-1460.

43. Kim HJ, Bae SC: **Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.** *Am J Transl Res* 2011, **3:**166-179.

44. Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R: **Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.** *Prostate* 2007, **67:**1182-1193.

45. Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC, Chen CS: **OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.** *Cancer Res* 2008, **68:**3999-4009.

46. He GH, Lin JJ, Cai WK, Xu WM, Yu ZP, Yin SJ, Zhao CH, Xu GL: **Associations of polymorphisms in histidine decarboxylase, histamine N-methyltransferase and histamine receptor H3 genes with breast cancer.** *PLoS One* 2014, **9:**e97728.

47. Roh T, Kwak MY, Kwak EH, Kim DH, Han EY, Bae JY, Bang du Y, Lim DS, Ahn IY, Jang DE, et al: **Chemopreventive mechanisms of methionine on inhibition of benzo(a)pyrene-DNA adducts formation in human hepatocellular carcinoma HepG2 cells.** *Toxicol Lett* 2012, **208:**232-238.

48. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB: **The role of inflammation in the pathogenesis of prostate cancer.** *J Urol* 2004, **172:**S6-11; discussion S11-12.

49. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, et al: **GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells.** *Am J Pathol* 2001, **159:**1815-1826.

50. Nelson CP, Kidd LC, Sauvageot J, Isaacs WB, De Marzo AM, Groopman JD, Nelson WG, Kensler TW: **Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1.** *Cancer Res* 2001, **61:**103-109.

51. Maldonado L, Brait M, Loyo M, Sullenberger L, Wang K, Peskoe SB, Rosenbaum E, Howard R, Toubaji A, Albadine R, et al: **GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.** *J Urol* 2014, **192:**1542-1548.

52. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, Vlassov VV, Laktionov PP: **Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients.** *Ann N Y Acad Sci* 2008, **1137:**222-225.

53. Dong H, Zhang H, Liang J, Yan H, Chen Y, Shen Y, Kong Y, Wang S, Zhao G, Jin W: **Digital karyotyping reveals probable target genes at 7q21.3 locus in hepatocellular carcinoma.** *BMC Med Genomics* 2011, **4:**60.

54. Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT: **Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker.** *PloS one* 2013, **8:**e59459.

55. Lapucci A, Lulli M, Amedei A, Papucci L, Witort E, Di Gesualdo F, Bertolini F, Brewer G, Nicolin A, Bevilacqua A, et al: **zeta-Crystallin is a bcl-2 mRNA binding protein involved in bcl-2 overexpression in T-cell acute lymphocytic leukemia.** *FASEB J* 2010, **24:**1852-1865.

56. Wang X, Zhang X, He P, Fang Y: **Sensitive detection of p53 tumor suppressor gene using an enzyme-based solid-state electrochemiluminescence sensing platform.** *Biosens Bioelectron* 2011, **26:**3608-3613.

57. Parkinson EK: **Senescence as a modulator of oral squamous cell carcinoma development.** *Oral Oncol* 2010, **46:**840-853.

58. Hickman JA, Potten CS, Merritt AJ, Fisher TC: **Apoptosis and cancer chemotherapy.** *Philos Trans R Soc Lond B Biol Sci* 1994, **345:**319-325.

59. Rokavec M, Li H, Jiang L, Hermeking H: **The p53/microRNA connection in gastrointestinal cancer.** *Clin Exp Gastroenterol* 2014, **7:**395-413.

60. Thomas P, Pang Y, Dong J, Berg AH: **Identification and Characterization of Membrane Androgen Receptors in the ZIP9 Zinc Transporter Subfamily: II. Role of Human ZIP9 in Testosterone-Induced Prostate and Breast Cancer Cell Apoptosis.** *Endocrinology* 2014, **155:**4250-4265.

61. Lin VC, Huang CY, Lee YC, Yu CC, Chang TY, Lu TL, Huang SP, Bao BY: **Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.** *Arch Toxicol* 2014, **88:**901-911.

62. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA: **An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.** *Cancer* 2012, **118:**6063-6071.

63. Wang W, Bergh A, Damber JE: **Increased p53 immunoreactivity in proliferative inflammatory atrophy of prostate is related to focal acute inflammation.** *APMIS* 2009, **117:**185-195.

64. Lu M, Xia L, Luo D, Waxman S, Jing Y: **Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis.** *Oncogene* 2004, **23:**3945-3952.

65. Roy S, Tenniswood M: **Site-specific acetylation of p53 directs selective transcription complex assembly.** *J Biol Chem* 2007, **282:**4765-4771.

Table Legends

Table 1 Primer sequences used in MSP

Table 2 Primer sequences used in qPCR

Table 3 Top 50 annotated genes with increased methylation, ranked by log2-fold change

Table 4 Top 50 annotated genes with decreased methylation, ranked by log2-fold change

Table 5 Top 10 altered canonical pathways, sorted by –log10 (P) value via IPA

Table 6 Top networks analyzed by IPA

Table 7 Altered methylation genes mapped to the neuropathic pain signaling pathway by IPA

Figure Legends

Fig. 1 Total mapping reads in the control and TRAMP mice (A) and the total number of significantly (log2-fold change ≥2) increased and decreased methylated genes in the TRAMP mice compared with the control mice (B)

Fig. 2 Heat-map of Top 100 decreased or increased (Log2-fold Change) methylated genes comparing with TRAMP to WT in different regions by MeDIP analysis, ranked by alphabetic.

Fig 3 Medip-Seq Validation by methylation-specific PCR (MSP). Representative electrophoretogram is presented in the top panel. M-MSP: methylated reaction of MSP, U-MSP: unmethylated reaction of MSP. The relative intensity of the methylated and unmethylated band was measured by ImageJ and presented in the bottom panel. All of the data are presented as the mean ± SD. \**p* < 0.05 versus the control WT group.

Fig. 4. Comparison of mRNA expression of CRYZ, DYNC1I1, HNMT, SLC1A4 and TTR among WT and TRAMP mice prostate samples. Total mRNA was isolated and analyzed using quantitative real-time PCR. The data are presented as the mean ± SD of three independent experiments. \**p* < 0.05 versus the control WT group.

Fig. 5. Top 5 associated disease categories (A) and top 5 cancer subtypes (B) analyzed by IPA

Fig. 6 Genes mapped to the canonical neuropathic pain signaling pathway by IPA. Red, increased methylation; green, decreased methylation (for interpretation of the references to color in the figure legend, please refer to the online version of this article)

Fig. 7 HDAC2 network (Score=38) (A), GSTP1 network (Score=16) (B), and UBC network (Score=16) (C), as determined by IPA. Red, increased methylation; green, decreased methylation (for interpretation of the references to color in the figure legend, please refer to the online version of this article)

Fig. 8 Merged network of the HDAC2 and GSTP1 networks, as determined by IPA. Red, increased methylation; green, decreased methylation (for interpretation of the references to color in the figure legend, please refer to the online version of this article)